SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-456145"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-456145" > Selpercatinib in RE...

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN) : a retrospective analysis of patients treated through an access program

Illini, Oliver (författare)
Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Klin Floridsdorf, Brunner Str 68, A-1210 Vienna, Austria.,Karl Landsteiner Inst Lung Res & Pulm Oncol, Austria
Hochmair, Maximilian Johannes (författare)
Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Klin Floridsdorf, Brunner Str 68, A-1210 Vienna, Austria.,Karl Landsteiner Inst Lung Res & Pulm Oncol, Austria
Fabikan, Hannah (författare)
Karl Landsteiner Inst Lung Res & Pulm Oncol, Klin Floridsdorf, Vienna, Austria.,Karl Landsteiner Inst Lung Res & Pulm Oncol, Austria
visa fler...
Weinlinger, Christoph (författare)
Karl Landsteiner Inst Lung Res & Pulm Oncol, Klin Floridsdorf, Vienna, Austria.,Karl Landsteiner Inst Lung Res & Pulm Oncol, Austria
Tufman, Amanda (författare)
LMU Munchen, Klinikum Univ Muenchen, Med Klin & Poliklin, Mitglied Deutsch Zentrums Lungenforsch, CPC M, Munich, Bayern, Germany.,LMU Munchen, Germany
Swalduz, Aurelie (författare)
Ctr Leon Berard, Lyon, France.,Ctr Leon Berard, France
Lamberg, Kristina (författare)
Uppsala universitet,Lung- allergi- och sömnforskning,Uppsala Univ Hosp, Sweden
Hashemi, Sayed M. S. (författare)
Vrije Univ Amsterdam, Med Ctr, Amsterdam UMC, Canc Ctr Amsterdam, Amsterdam, Netherlands.,Vrije Univ Amsterdam, Netherlands
Huemer, Florian (författare)
Ludwig Boltzmann Inst Lung Hlth, Dept Resp Care, Klin Penzing, Vienna, Austria.,Ludwig Boltzmann Inst Lung Hlth, Austria
Vikström, Anders (författare)
Linköpings universitet,Institutionen för klinisk och experimentell medicin,Hälsouniversitetet,Region Östergötland, Lungmedicinska kliniken US,Linkoping Univ Hosp, Pulm clin, Linkoping, Sweden.
Wermke, Martin (författare)
Tech Univ Dresden, Med Fac C G Carus, NCT UCC Early Clin Trial, Unit Dresden, Dresden, Germany.,Tech Univ Dresden, Germany
Absenger, Gudrun (författare)
Med Univ Graz, Dept Oncol, Graz, Austria.,Med Univ Graz, Austria
Addeo, Alfredo (författare)
Univ Hosp Geneva, Oncol Dept, Geneva, Switzerland.,Univ Hosp Geneva, Switzerland
Banerji, Shantanu (författare)
Univ Manitoba, Res Inst Oncol & Hematol, Canc Care Manitoba, Winnipeg, MB, Canada.,Univ Manitoba, Canada
Calles, Antonio (författare)
Univ Gregorio Maranon, Hosp Gen, Med Oncol Dept, Madrid, Spain.,Univ Gregorio Maranon, Spain
Clarke, Stephen (författare)
Royal North Shore Hosp, Med Oncol Unit, St Leonards, NSW, Australia.,Royal North Shore Hosp, Australia
Di Maio, Massimo (författare)
Univ Turin, Dept Oncol, Turin, Italy.;Ordine Mauriziano Hosp, Med Oncol, Turin, Italy.,Univ Turin, Italy; Ordine Mauriziano Hosp, Italy
Durand, Alice (författare)
Univ Lyon, France Univ Claude Bernard Lyon 1, Hosp Civils Lyon, Canc Inst Lyon,Louis Pradel Hosp,Resp Dept, Lyon, France.,Univ Lyon, France
Duruisseaux, Michael (författare)
Hosp Civils Lyon, Canc Inst, Louis Pradel Hosp, Resp Dept, Lyon, France.;Canc Res Ctr Lyon, Oncopharmacol Lab, Lyon, France.;Univ Lyon, Univ Claude Bernard Lyon 1, Lyon, France.,Hosp Civils Lyon, France; Canc Res Ctr Lyon, France; Univ Lyon, France
Itchins, Malinda (författare)
Royal North Shore Hosp, Med Oncol Unit, St Leonards, NSW, Australia.,Royal North Shore Hosp, Australia
Kääränien, Okko-Sakari (författare)
Kuopio Univ Hosp, Ctr Canc, Kuopio, Finland.
Krenn, Florian (författare)
LKH Hochsteiermark Standort Leoben, Abt Lungenkrankheiten, Leoben, Austria.,LKH Hochsteiermark Standort Leoben, Austria
Laack, Eckart (författare)
Studiengesellschaft Hamatoonkol Hamburg, Hamburg, Germany.,Studiengesellschaft Hamatoonkol Hamburg, Germany
de Langen, Adrianus Johannes (författare)
Netherlands Canc Inst, Amsterdam, Netherlands.,Netherlands Canc Inst, Netherlands
Mohorcic, Katja (författare)
Univ Clin Goln, Med Oncol Unit, Golnik, Slovenia.,Univ Clin Goln, Slovenia
Pall, Georg (författare)
Univ Innsbruck Hosp, Dept Internal Med V Hematol Oncol, Innsbruck, Austria.,Univ Innsbruck Hosp, Austria
Passaro, Antonio (författare)
European Inst Oncol IRCCS, Div Thorac Oncol, Milan, Italy.,European Inst Oncol IRCCS, Italy
Prager, Gerald (författare)
Comprehens Canc Ctr Vienna, Dept Med I, Vienna, Austria.,Comprehens Canc Ctr Vienna, Austria
Rittmeyer, Achim (författare)
LKI Lungenfachklin Immenhausen, Dept Thorac Oncol, Immenhausen, Germany.,LKI Lungenfachklin Immenhausen, Germany
Rothenstein, Jeffrey (författare)
R.S. McLaughlin Durham Regional Cancer Center at Lakeridge Health, Adjunct Assistant Professor Queen’s University, Ontario, Canada
Schumacher, Michael (författare)
Department of Pneumology, Ordensklinikum Elisabethinen Linz, Linz, Austria
Woell, Ewald (författare)
Department Internal Medicine, St. Vinzenz Krankenhaus Betriebs GmbH, Sanatoriumstr. 43, 6511 Zams, Austria
Valipour, Arschang (författare)
Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna
Kaaranien, Okko-Sakari (författare)
Kuopio Univ Hosp, Finland
visa färre...
Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Klin Floridsdorf, Brunner Str 68, A-1210 Vienna, Austria Karl Landsteiner Inst Lung Res & Pulm Oncol, Austria (creator_code:org_t)
SAGE PUBLICATIONS LTD, 2021
2021
Engelska.
Ingår i: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. - : SAGE PUBLICATIONS LTD. - 1758-8340 .- 1758-8359. ; 13
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have shown therapeutic activity in early clinical trials; however, their efficacy in the real-world setting is unknown. Methods: A retrospective efficacy and safety analysis was performed on data from RET fusion-positive NSCLC patients who participated in a selpercatinib access program (named patient protocol) between August 2019 and January 2021. Results: Data from 50 patients with RET fusion-positive advanced NSCLC treated with selpercatinib at 27 centers in 12 countries was analyzed. Most patients were Non-Asian (90%), female (60%), never-smokers (74%), with a median age of 65 years (range, 38-89). 32% of the patients had known brain metastasis at the time of selpercatinib treatment. Overall, 13 patients were treatment-naive, while 37 were pretreated with a median of three lines of therapy (range, 1-8). The objective response rate (ORR) was 68% [95% confidence interval (CI), 53-81] in the overall population. The disease control rate was 92%. The median progression-free survival was 15.6 months (95% CI, 8.8-22.4) after a median follow-up of 9 months. In patients with measurable brain metastases (n = 8) intracranial ORR reached 100%. In total, 88% of patients experienced treatment-related adverse events (TRAEs), a large majority of them being grade 1 or 2. The most common grade > 3 TRAEs were increased liver enzyme levels (in 10% of patients), prolonged QTc time (4%), abdominal pain (4%), hypertension (4%), and fatigue/asthenia (4%). None of patients discontinued selpercatinib treatment for safety reasons. No new safety concerns were observed, nor where there any treatment-related death. Conclusions: In this real-world setting, the selective RET-inhibitor selpercatinib demonstrated durable systemic and intracranial antitumor activity in RET fusion-positive NSCLC and was well tolerated.

Ämnesord

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)

Nyckelord

non-small cell lung cancer (NSCLC)
real-world data
RET gene fusions
selpercatinib
targeted therapy
tyrosine kinase inhibitor (TKI)
non-small cell lung cancer (NSCLC); real-world data; RET gene fusions; selpercatinib; targeted therapy; tyrosine kinase inhibitor (TKI)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy